The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...

Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise ...

The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which ...

The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin and muscle disorder but missed in a lupus study.

The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely followed lung disease medicine.

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.

Today, a brief rundown of news from Johnson & Johnson and Pfizer, as well as updates from Gilead Sciences, Link Cell Therapies and Sanofi that you may have missed. Striking study results last year ...

Xoma Royalty, which has recently built a business out of acquiring struggling biotechnology companies, has secured its latest target. In announcement late Monday, Xoma said it has agreed to pay about ...

Kyverna Therapeutics will seek clearance of what could be the first marketed cell therapy for an autoimmune condition after the treatment succeeded in a pivotal trial in a progressive condition known ...